Molecular evidence underlying specific immunotherapy in patients with allergic rhinitis
- Conditions
- Allergic rhinitisInflammatory and Immune System - Allergies
- Registration Number
- ACTRN12613000445774
- Lead Sponsor
- i Tian Ying
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Patients were (1) age from 20 to 45 years old; (2) having persistent AR symptoms during the past two consecutive years; (3) allergic sensitization to Dermatophagoides pteronyssinus, (Der p) & Dermatophagoides farina (Der f)) confirmed by both skin prick test (SPT) and ImmunoCap (Registered Trademark) (Phadia, Uppsala, Sweden); (4) no previous treatment of SIT; and (5) negative SPT results to other common inhalant allergens (e.g., common pollens, cockroach, fungi, and animal dander). Healthy subjects without any allergy history and allergic symptoms were selected as a control group.
All recruited subjects (both allergic rhintis patients and healthy controls) did not have an infection, asthma, autoimmune diseases, or other upper airway diseases such as septal deviation, nasal polyps, or sinusitis before enrolment. Furthermore, all participants had not received any form of steroids or SIT at least six months before the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms assessed by visual analogue scale (VAS). The subjects were instructed that Score 0” meant overall symptoms not all bothersome” and that Score 10” meant overall symptoms extremely bothersome”. [2 years after administration]
- Secondary Outcome Measures
Name Time Method Th17 response was inhibited by immunotherapy in patients with allergic rhinitis, by assessing the expression levels of Th17 associated genes.[2 years after adminstration]